Only a small proportion of patients with cancer show lasting responses to immune
checkpoint blockade (ICB)-based monotherapies. The RNA-editing enzyme ADAR1 is an …

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …

The integration of mass spectrometry-based proteomics with next-generation DNA and RNA
sequencing profiles tumors more comprehensively. Here this" proteogenomics" approach …

Gliomas are the most aggressive primary intracranial malignancies with poor overall
survival. ITGA5 is one member of the integrin adhesion molecule family and is implicated in …

Objectives Transcriptomic-based subtyping, consensus molecular subtyping (CMS) and
colorectal cancer intrinsic subtyping (CRIS) identify a patient subpopulation with …

Purpose Recent studies have increasingly linked Ephrin receptor B2 (EPHB2) to cancer
progression. However, comprehensive investigations into the immunological roles and …

Immuno-oncology holds promise for transforming patient care having achieved durable
clinical response rates across a variety of advanced and metastatic cancers. Despite these …

Background Immune checkpoint inhibitors (ICIs) have revolutionized gastrointestinal cancer
treatment, yet the absence of reliable biomarkers hampers precise patient response …

The biological and clinical heterogeneity of neuroblastoma (NB) demands novel biomarkers
and therapeutic targets in order to drive the most appropriate treatment for each patient …